DelveInsight’s “Systemic Sclerosis-associated Interstitial Lung Disease Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the SSc-ILD treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and SSc-ILD market forecasts through 2034, providing crucial insights for stakeholders in the systemic sclerosis therapeutic area.
According to DelveInsight’s analysis, the systemic sclerosis-associated interstitial lung disease market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of one-time gene therapies, and raised awareness during the forecast period (2024-2034).
Furthermore, the United States accounts for the largest systemic sclerosis-associated interstitial lung disease market size in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Understand which factors are driving the SSc-ILD therapeutic market @ SSc-ILD Market Trends.
As per DelveInsight’s analysis, the SSc-ILD is dominant among females in the US mainly due to the higher prevalence of systemic sclerosis in women, which is likely driven by complex genetic and hormonal factors. Additionally, severity-specific prevalence data suggest that the cases of the moderate type are much higher than the severe type of SSc-ILD.
Among EU4 and the UK, the United Kingdom had the highest diagnosed prevalent cases of SSc-ILD in 2023, followed by Italy and France, while Germany had the lowest diagnosed prevalent cases in the same year. The UK also constituted the highest systemic sclerosis-associated interstitial lung disease market size among EU4 and the UK region in 2023.
Discover evolving trends in the SSc-ILD patient pool forecasts @ SSc-ILD Epidemiology Analysis.
Systemic Sclerosis (SSc) is characterized by fibrosis, vasculopathy, and inflammation that may affect different organs and systems, with severe prognostic implications. When SSc manifests at the lung level, the pulmonary disease may manifest as interstitial lung disease (ILD) and/or pulmonary arterial hypertension (PAH). Patients with SSc have a high probability of developing ILD as a complication, and this combination of SSc-ILD can cause lung inflammation and scarring that lead to breathing failure.
The SSc-ILD treatment historically involved immunosuppressive agents, with hematopoietic stem cell transplantation (HSCT) and lung transplantation reserved for severe or rapidly progressive cases. The standard of care now includes cyclophosphamide and mycophenolate mofetil, albeit with modest improvements in forced vital capacity (FVC). Currently, two FDA-approved therapies represent significant milestones in SSc-ILD treatment.
ACTEMRA/ROACTEMRA (tocilizumab) by Roche received FDA approval in March 2021 for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease. Tocilizumab is a monoclonal antibody that selectively binds to the interleukin-6 receptor and prevents IL-6 from binding to its receptor on the liver, lung, and synovial fibroblasts.
OFEV (nintedanib) by Boehringer Ingelheim was approved by the FDA in 2019 as the first and only medicine to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. OFEV’s active ingredient nintedanib is a tyrosine kinase inhibitor (TKI) that inhibits the growth factor receptors involved in the pulmonary fibrosis progression.
According to the DelveInsight report, the SSc-ILD therapies pipeline shows promising developments with several novel treatments in various stages of clinical development. GSK1550188/Belimumab (BENLYSTA) by GlaxoSmithKline is a fully human monoclonal antibody that prevents B cells from differentiating. The company initiated a Phase III trial of belimumab for SSc-ILD in September 2023, and in February 2023, the FDA granted Orphan Drug Designation to BENLYSTA to treat SSc.
PRA023 by Merck (formerly Prometheus Biosciences) is a humanized IgG1 monoclonal antibody with a dual mechanism of action, targeting both inflammation and fibrosis. In January 2022, the FDA granted Fast Track Designation for PRA023 to treat SSc-ILD, and the drug is currently in Phase II development.
Discover recent advancements in the SSc-ILD treatment landscape @ SSc-ILD Recent Developments.
The systemic sclerosis-associated interstitial lung disease treatment market is highly competitive, with major players including Roche, Boehringer Ingelheim, Genentech (a member of the Roche Group), GlaxoSmithKline, Merck & Co, Prometheus Biosciences, Acceleron Biosciences, Talaris Therapeutics, and Kadmon, all advancing a variety of therapies through robust research and development initiatives and strategic collaborations.
Looking ahead, the SSc-ILD market is expected to witness continued innovation driven by enhanced understanding of disease mechanisms and personalized medicine approaches. While significant progress has been made with current therapies, challenges remain in addressing disease progression, improving patient outcomes, and ensuring treatment accessibility across diverse patient populations. Emerging therapies focusing on novel mechanisms and targeted approaches hold promise for addressing these unmet needs and further transforming the SSc-ILD treatment landscape.
DelveInsight’s analysis underscores the substantial opportunities that remain for developing more effective, convenient, and affordable treatment options that can slow disease progression and improve quality of life for SSc-ILD patients worldwide. As research continues and awareness grows, the systemic sclerosis-associated interstitial lung disease market is poised for remarkable expansion and therapeutic innovation.
Table of Contents
1. Key Insights
2. Executive Summary of SSc-ILD
3. Competitive Intelligence Analysis for SSc-ILD
4. SSc-ILD Market Overview at a Glance
5. SSc-ILD: Disease Background and Overview
6. SSc-ILD Patient Journey
7. SSc-ILD Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. SSc-ILD Unmet Needs
10. Key Endpoints of SSc-ILD Treatment
11. SSc-ILD Marketed Products
12. SSc-ILD Emerging Therapies
13. SSc-ILD: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of SSc-ILD
17. KOL Views
18. SSc-ILD Market Drivers
19. SSc-ILD Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Systemic Sclerosis Associated Interstitial Lung Disease Pipeline Insight
SSc-ILD pipeline insight provides comprehensive insights about the SSc-ILD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the SSc-ILD companies, including aTyr Pharma, Roche, Boehringer Ingelheim, Acceleron Biosciences, Talaris Therapeutics, and Kadmon, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services